SCHEMBL17818383

SCHEMBL17818383

C#Cc1cccc(S(=O)(=O)Nc2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 3/20 0.59
POLB P06746 1/20 0.59
KEAP1 Q14145 2/20 0.59
IL1RN P18510 1/20 0.59
ERAP1 Q9NZ08 1/20 0.59
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
PKM P14618 2/20 0.56
ALDH1A1 P00352 1/20 0.56
CA12 O43570 2/20 0.56
CA9 Q16790 2/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA14 Q9ULX7 1/20 0.56
IDH1 O75874 1/20 0.53
HTR6 P50406 3/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16254730 0.90 HTR6 (0.59) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL19334523 0.84 PGR (0.77) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL8081768 0.82 KEAP1 (0.79) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL19994718 0.81 KMT2A (0.67) PGRKEAP1IL1RNERAP1KMT2A
SCHEMBL1403233 0.81 PGR (0.52) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL1403178 0.79 HDAC8 (0.56) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL17818389 0.78 CA12 (0.61) CA12CA9CA1CA2CA14
SCHEMBL28021810 0.77 CA12 (0.59) POLBKMT2AMEN1ALDH1A1CA12
SCHEMBL25031372 0.76 KEAP1 (1.00) PGRPOLBKEAP1IL1RNERAP1
Phenyl(Phenylsulfonyl)Amine SCHEMBL114765 0.76 KEAP1 (1.00) PGRPOLBKEAP1IL1RNERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230201161-A1 Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment 4SC AG (DE) 2023-06-29 US disclosed
EP-2997030-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-08-09 EP disclosed
US-9682083-B2 Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-20 US disclosed
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-06-16 US disclosed
CN-105431436-A Pyrrolo [2,3-D ] pyrimidine derivatives, processes for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2016-03-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS RET, DCK, PRKD2 PGR 2829/4885POLB 1308/4885KEAP1 2238/4885
US-20230201161-A1 Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment HDAC1, HDAC3, HDAC11 PGR 3798/4885POLB 3353/4885KEAP1 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.